FindTrial
Sign In

The study and clinical application of a novel broad-spectrum inflammatory imaging probe-99mTc-cFLFLF(antagonist of leukocyte FPR)

The study and clinical application of a novel broad-spectrum inflammatory imaging probe-99mTc-cFLFLF(antagonist of leukocyte FPR)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DPD-17011933
Enrollment
Unknown
Registered
2017-07-10
Start date
2017-02-27
Completion date
Unknown
Last updated
2017-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation

Interventions

Gold Standard:Gold Standard:pathology
Reference Standard:1.CT?MRI
2.The anti-inflammatory treatment improve disease.
Index test:99mTc-cFLFLF

Sponsors

the Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients suffer bacterial inflammation or non-bacterial inflammation, such as pneumonia, osteomyelitis, arthritis, and so on; 2. To differential diagnose inflammatory nodule in lung and pulmonary tumor; 3. To differential diagnose bone metastasis and inflammation; 4. To confirm extent of inflammation after operation.

Exclusion criteria

Exclusion criteria: 1. pregnant woman; 2. age80 years.

Design outcomes

Primary

MeasureTime frame
99mTc-cFLFLF imaging;—

Countries

China

Contacts

Public ContactGengbiao Yuan

Chongqing Medical University

Yuan_gb@126.com+86 13668047619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026